Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

医学 内科学 肾细胞癌 胃肠病学 乳头状肾细胞癌 皮疹 肾癌 肿瘤科 无进展生存期 肾透明细胞癌 埃罗替尼 癌症 化疗 表皮生长因子受体
作者
Ramaprasad Srinivasan,Sandeep Gurram,Eric A. Singer,Abhinav Sidana,Munjid Al Harthy,Mark Wayne Ball,Julia C. Friend,Lisa Marie Mac,Erin Purcell,Cathy D. Vocke,Christopher J. Ricketts,Heidi H. Kong,Edward W. Cowen,Ashkan A. Malayeri,Joanna H. Shih,Maria J. Merino,William Marston Linehan
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:392 (23): 2346-2356 被引量:43
标识
DOI:10.1056/nejmoa2200900
摘要

BACKGROUND: Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of papillary renal-cell carcinoma. No effective therapy is known for patients with advanced HLRCC-associated papillary renal-cell carcinoma, and most patients die from progressive disease. METHODS: In this open-label, phase 2 study, we evaluated the efficacy of bevacizumab (10 mg per kilogram of body weight every 2 weeks) and erlotinib (150 mg once daily) in patients with advanced HLRCC-associated or sporadic papillary renal-cell carcinoma. The primary end point was overall response; secondary end points included progression-free and overall survival. RESULTS: A total of 43 patients with HLRCC-associated papillary renal-cell carcinoma and 40 patients with sporadic papillary renal-cell carcinoma were enrolled. A confirmed response occurred in 31 patients (72%; 95% confidence interval [CI], 57 to 83) with HLRCC-associated papillary renal-cell carcinoma; the median progression-free survival was 21.1 months (95% CI, 15.6 to 26.6), and the median overall survival was 44.6 months (95% CI, 32.7 to could not be estimated). A confirmed response occurred in 14 patients (35%; 95% CI, 22 to 51) with sporadic papillary renal-cell carcinoma, with a median progression-free survival of 8.9 months (95% CI, 5.5 to 18.3) and a median overall survival of 18.2 months (95% CI, 12.6 to 29.3). The most common treatment-related adverse events were acneiform rash (93%), diarrhea (89%), and proteinuria (78%). The most common treatment-related adverse events of grade 3 or higher were hypertension (34%) and proteinuria (17%). CONCLUSIONS: The combination of bevacizumab and erlotinib showed antitumor activity in patients with HLRCC-associated or sporadic papillary renal-cell carcinoma. Toxic effects were those known to be associated with this combination. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT01130519.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开朗的天佑完成签到,获得积分10
刚刚
erlangenbio发布了新的文献求助10
刚刚
甜蜜板栗完成签到 ,获得积分10
1秒前
科研通AI2S的应助被害怕的慕晴采纳,获得10
1秒前
2秒前
2秒前
3秒前
归帆关注了科研通微信公众号
4秒前
4秒前
5秒前
粒橙酱完成签到,获得积分10
6秒前
马亚斌发布了新的文献求助10
6秒前
庾楼月宛如昨完成签到 ,获得积分10
7秒前
8秒前
8秒前
杜欣悦发布了新的文献求助10
9秒前
9秒前
多看点文献吧完成签到,获得积分10
9秒前
思源的应助被nxdr采纳,获得10
10秒前
冯梦梦完成签到,获得积分10
11秒前
之子之远完成签到,获得积分10
11秒前
传奇3的应助被MADAO采纳,获得30
13秒前
大白完成签到 ,获得积分10
13秒前
CITY111119发布了新的文献求助10
13秒前
13秒前
13秒前
zww113发布了新的文献求助10
13秒前
14秒前
冯梦梦发布了新的文献求助10
14秒前
童童完成签到,获得积分10
15秒前
15秒前
7ian完成签到 ,获得积分10
16秒前
欢喜夏天完成签到,获得积分10
16秒前
清辉影的应助被漫漫采纳,获得10
17秒前
18秒前
等风归发布了新的文献求助10
19秒前
20秒前
昏睡的绿海完成签到,获得积分10
20秒前
AKKK完成签到 ,获得积分10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621